Pilot study: Biomarkers for the diagnosis of severe neutrophil inflammatory asthma.

Pilot study: Biomarkers for the diagnosis of severe neutrophil inflammatory asthma. - Biomarkers for severe neutrophil inflammatory asthma

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON42933

Enrollment

Registered

2017-02-22

Start date

2017-07-14

Completion date

Unknown

Last updated

2024-04-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Severe asthma

Interventions

None listed

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: All patients included in this study suffer from severe asthma. When a diagnosis of asthma is confirmed and comorbidities have been addressed, severe asthma is defined as asthma which requires treatment with high dose inhaled corticosteroids (ICS) plus a second controller (and/or systemic CS) to prevent it from becoming *uncontrolled* or which remains *uncontrolled* despite this therapy.

Exclusion criteria

Exclusion criteria: -People suffering from other (chronic, pulmonary or autoimmune) diseases than asthma -People suffering from an upper or lower respiratory infection within four weeks prior to investigation -People having an immunodeficiency -People taking antibiotics (macrolide trial included) or probiotics, four weeks prior to investigation -People taking oral corticosteroids -People who smoke.

Design outcomes

Primary

Measure	Time frame
Th1/Th2/Th17 patterns by analysing cytokine concentrations (Th1: IL-2, TNF, IFNγ; Th2: IL-4, IL-6, IL-10; Th17: IL-17A) in nasal fluid (nasal wash and cotton wool method), saliva and blood.	—

Secondary

Measure	Time frame
n.a.	—

Countries

Netherlands

Outcome results